Opinion

Video

Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

Author(s):

Catherine C. Coombs, MD,Matthew S. Davids, MD, MMSc

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.

  1. The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Nitin Jain, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
David C. Fisher, MD, of Dana-Farber Cancer Institute
October 21st 2024

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Nitin Jain, MD, professor, medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center
October 14th 2024

BTK Inhibitors vs Venetoclax: Considerations for Frontline Treatment Selection in CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Jeanette Lundin, MD, PhD, Karolinska University Hospital
October 8th 2024

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

Javier Pinilla-Ibarz, MD, PhD, senior member, head, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center
September 9th 2024

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL